Aurinia’s board gets pushback from another shareholder as Iljin follows MKT Capital’s lead
It’s the not-so-lucky seven for Aurinia Pharmaceuticals.
Korean investor Iljin SNT is withholding support for seven of the Canadian biotech’s eight board members, backing only the CEO Peter Greenleaf.
Iljin, a 4.3% shareholder, is echoing MKT Capital, which owns 4.2% of the shares, in calling for a board shakeup at the drug developer. Aurinia markets Lupkynis for lupus nephritis and has two preclinical assets through external deals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.